An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

NCT01970111 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-04-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients.

Conditions

  • Spinocerebellar Degeneration

Interventions

DRUG

KPS-0373, High dose

DRUG

KPS-0373, Low dose

Sponsors & Collaborators

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2015-07-31

Countries

  • Japan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01970111 on ClinicalTrials.gov